A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Higher Risk Myelodysplastic Syndromes Clinical Trial

Official title: A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02)

Status Active, not recruiting

Clinical Trial Summary

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

Clinical Trial Description

The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in combination with azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination with azacitidine compared to azacitidine alone for patients with previously untreated higher risk MDS. ;

Related Conditions & MeSH terms

• Higher Risk Myelodysplastic Syndromes
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

• NCT number: NCT04417517
• Study type: Interventional
• Source: ALX Oncology Inc.
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2, 2020
• Completion date: June 30, 2024